Imbria's Orphan Drug Win: A New Strategy in the Race to Treat nHCM

BOSTON, MA – June 24, 2026 – In a significant move that underscores a shift in cardiovascular therapy, clinical-stage biotech firm Imbria Pharmaceuticals announced today it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ninerafaxstat. The drug is an investigational oral therapy aimed at a long-neglected patient population: those with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). This designation is more than a regulatory footnote; it is a strategic accelerant for Imbria and a powerful signal of hope for a community with no approved treatments.

While recent breakthroughs have targeted the obstructive form of HCM, nHCM patients have remained in a therapeutic void. The FDA’s decision validates ninerafaxstat’s potential and provides Imbria with critical incentives to navigate the costly and complex path to market. It also highlights an emerging front in cardiac medicine, where fixing the heart’s energy supply may prove as crucial as managing its mechanical function.

The Unseen Burden of a Thickened Heart

Hypertrophic cardiomyopathy (HCM), the most common inherited cardiac disease, affects roughly 1 in 500 people. It is defined by an abnormal thickening of the heart muscle. While attention has historically focused on the obstructive form (oHCM), where thickened muscle blocks blood flow, about a third of patients suffer from the non-obstructive variant. In nHCM, the heart muscle is stiff and unable to relax and fill properly, a state of diastolic dysfunction that compromises cardiac efficiency.

The term “non-obstructive” belies the severity of the condition. Patients often endure a debilitating array of symptoms that erode their quality of life. According to patient surveys and clinical studies, nearly 90% report profound fatigue and shortness of breath, with a majority also experiencing dizziness, chest pain, and palpitations. These symptoms transform everyday activities into significant challenges, casting a long shadow over physical and emotional well-being. Despite this burden, and the associated risks of atrial fibrillation, stroke, and heart failure, there are no FDA-approved therapies specifically designed for nHCM. Current care relies on off-label use of beta-blockers and calcium channel blockers, which only manage symptoms and do not address the disease's underlying pathology.

A Novel Strategy: Recharging the Heart's Engine

Ninerafaxstat represents a fundamentally different approach. It is not designed to alter the heart’s contractility but to optimize its energy metabolism. As a first-in-class partial fatty acid oxidation (pFOX) inhibitor, the drug targets the heart's cellular engine: the mitochondria. A healthy heart generates energy by metabolizing both fatty acids and glucose. In pathological states like HCM, the heart can become overly reliant on fatty acids—a less efficient fuel source that demands more oxygen to produce the same amount of energy (ATP).

Ninerafaxstat works by partially inhibiting this process, compelling the heart to shift its fuel preference toward glucose. This metabolic switch allows the heart to produce energy more efficiently, potentially improving cardiac function without altering blood pressure or heart rate. It’s an elegant strategy focused on resilience, aiming to restore the heart's energetic balance rather than forcing a mechanical change.

This scientific premise is backed by promising clinical data. The Phase 2a IMPROVE-HCM trial, whose results were presented at the American College of Cardiology’s 2024 scientific session, showed that ninerafaxstat was well-tolerated and produced statistically significant improvements in ventilatory efficiency during exercise—a key predictor of outcomes in HCM. Furthermore, the drug led to a reduction in left atrial size, an objective marker of improved diastolic function. These results provided the foundation for advancing the drug into its current, larger Phase 2b FORTITUDE-HCM trial.

The Strategic Power of Orphan Status

For Imbria, the Orphan Drug Designation is a critical strategic asset. This status is reserved for treatments for rare conditions affecting fewer than 200,000 people in the U.S., and it confers substantial advantages. The most significant is the potential for seven years of market exclusivity upon approval, a powerful shield against competition that stands independent of the company's existing patents, which extend to 2038 and beyond. This exclusivity provides a protected runway to establish ninerafaxstat as a standard of care.

Beyond exclusivity, the designation provides tangible financial benefits, including tax credits for clinical trial costs and a waiver of the multi-million-dollar Prescription Drug User Fee Act (PDUFA) fees required for a new drug application. It also grants Imbria enhanced access to FDA guidance, streamlining the development process.

“Receiving Orphan Drug Designation for ninerafaxstat is an important milestone as we advance its development for patients living with symptomatic nHCM, a population with significant unmet medical need,” said Alvin Shih, MD, Chief Executive Officer of Imbria. He noted the drug's potential as a standalone or combination therapy and confirmed the company anticipates topline data from the ongoing FORTITUDE-HCM trial in the first half of 2027.

Navigating a Shifting Competitive Landscape

Imbria’s progress does not occur in a vacuum. The therapeutic landscape for HCM is evolving rapidly, creating both opportunities and challenges. The primary competitors are cardiac myosin inhibitors, which reduce hypercontractility. While Bristol Myers Squibb’s mavacamten (Camzyos) succeeded in oHCM, its Phase 3 trial in nHCM failed to meet its primary endpoints, underscoring that the two conditions may require different therapeutic strategies.

However, a more direct competitor has emerged. Cytokinetics recently announced positive topline results from the Phase 3 trial of its myosin inhibitor, aficamten, in nHCM, showing significant improvements in both symptoms and exercise capacity. If approved, aficamten could become the first therapy specifically indicated for nHCM, setting a high bar for any subsequent market entrant.

This is where ninerafaxstat’s differentiated mechanism becomes its core strength. By targeting metabolism instead of contractility, it offers a distinct and potentially complementary approach. For patients who do not respond to or cannot tolerate myosin inhibitors, a metabolic modulator could provide a vital alternative. The clean safety profile observed thus far, with no adverse effects on cardiac function, further strengthens its case as a foundational therapy. As Imbria pushes forward with its FORTITUDE-HCM trial, the results anticipated in 2027 will be pivotal in defining ninerafaxstat’s role in this new era of cardiac care and its potential to deliver lasting value for both patients and investors.